-
1 Comment
Cryosite Limited is currently in a long term uptrend where the price is trading 23.5% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.1.
Cryosite Limited's total revenue rose by 18.5% to $5M since the same quarter in the previous year.
Its net income has dropped by 77.2% to $285K since the same quarter in the previous year.
Finally, its free cash flow fell by 92.0% to $43K since the same quarter in the previous year.
Based on the above factors, Cryosite Limited gets an overall score of 3/5.
Exchange | AU |
---|---|
CurrencyCode | AUD |
Sector | Healthcare |
Industry | Diagnostics & Research |
ISIN | AU000000CTE1 |
PE Ratio | 21.5 |
---|---|
Dividend Yield | 0.0% |
Beta | 0.3 |
Target Price | None |
Market Cap | 42M |
Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen, Ultra-frozen and cryogenic, and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements. The Ultra-frozen and cryogenic segment offers advanced therapy medicinal products (ATMPS), such as cell and gene therapies (CGT), cell therapies, mRNA-based medicines, biological samples, and research and development materials requiring high-integrity cold storage. The Cord Blood segment provides storage of cord blood cell and tissue samples for personal or directed therapeutic use by maintaining under validated chain-of-identity controls. It also, offers reverse logistics services, secondary packaging, and quality transportation and distribution solutions. Cryosite Limited was incorporated in 1999 and is based in South Granville, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CTE.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025